The gold standard for diagnosing liver disease is a liver biopsy, but researchers are seeking a simpler way to identify those at risk, given the silent nature of early disease and rising incidence around the globe.
In a recent study, researchers said they found a biomarker that can be used to diagnosis nonalcoholic fatty liver disease (NAFLD), the most common liver disease worldwide and a risk factor for cirrhosis, liver failure or cancer.
Currently, diagnosing NAFLD or nonalcoholic steatohepatitis (NASH) requires an invasive needle biopsy, which carries risks of complications, sampling errors, and cost. With the incidence of NAFLD increasing, affecting one-fourth of the world’s population due to rising obesity, and because the beginning stages of liver damage are asymptomatic, there is a need for earlier, easier identification methods, said the authors, writing in Hepatology.
Researchers from Japan and the United Kingdom conducted a retrospective multicenter cohort study, enrolling a total of 311 biopsy-proven NAFLD patients diagnosed in 3 Japanese hospitals between 2014 and 2020.
Inclusion criteria included the presence of fatty liver by liver imaging test, persistent increases in liver enzyme levels, the absence of chronic liver disease other than NAFLD, and alcohol consumption less than 20 grams per day.
Using whole-genome transcriptomics, they analyzed liver tissues from 98 patients with biopsy-proven NAFLD (51 with NAFL and 47 with NASH).
The analysis identified proteins predicted to be secreted from the liver, including matricellular glycoprotein thrombospondin-2 (TSP-2), encoded by the thrombospondin 2 (THBS2) gene.
THBS2 expression in liver cells paralleled the inflammation and ballooning that signal disease, including serum enzyme levels, NAFLD Activity Score and NAFLD Fibrosis Score. THBS2 was linked with "extracellular matrix and collagen biosynthesis, platelet activation, caspase-mediated cleavage of cytoskeletal proteins, and immune cell infiltration," the report said.
Serum TSP-2 level and platelet count were independent predictors of NASH and advanced fibrosis, and serum TSP-2 levels could stratify patients according to the risk of hepatic complications, including liver cancer and decompensated cirrhotic events, such as esophageal varix, ascites, and hepatic encephalopathy.
"Serum levels of TSP-2 in NAFLD patients were significantly higher in NASH than in NAFL," author Takahiro Kodama, MD, Department of Gastroenterology and Hepatology, Osaka Graduate School of Medicine, Suita, Japan, said in a statement. Notably, "the increase tallied with the degree of fibrosis," he added.
In addition, the authors identified 136 significantly upregulated genes possibly involved in molecular pathogenesis of NASH; they found overlap with 95 genes upregulated in the transcriptome dataset of patients with NAFLD in a European registry; the "overlap strengthens the validity of our transcriptome analysis," the authors said.
Reference
Kozumi K, Kodama T, Murai H, et al. Transcriptomics identify thrombospondin-2 as a biomarker for nonalcoholic steatohepatitis and advanced liver fibrosis. Hepatology. Published online June 9, 2021 doi: 10.1002/hep.31995
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More